Direkt zum Inhalt
Merck

Fortfahren mit

74817

FITC-CM-Dextran

average mol wt 150,000

Synonym(e):

FITC-CM-Dextran 150, Fluoresceinisothiocyanat-Carboxymethyl–Dextran

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
1 g
Warenkorb auf Verfügbarkeit prüfen
€ 234,00

Über diesen Artikel

NACRES:
NA.32
UNSPSC Code:
12352108

€ 234,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


biological source

synthetic

Quality Level

conjugate

FITC conjugate

form

powder or crystals

mol wt

average mol wt 150,000

composition

carboxymethyl content, 3-7%

extent of labeling

0.001-0.020 mol FITCmol glucose

fluorescence

λex 493 nm; λem 517 nm±5 nm in 0.1 M Tris pH 8.0

General description

FITC-CM-Dextran, also known as Fluorescein isothiocyanate–Carboxymethyl–Dextran, is an anionic fluorescent probe. The carboxyl group provides the negative charge, which improves the overall permeability of the molecule. It is supplied as a yellow powder that is freely soluble in water and electrolyte solutions. FITC-CM-Dextran is insoluble in most organic samples such as ethanol, methanol, acetone, and chloroform.

FITC-CM-Dextran is manufactured by reacting selected dextran fractions with an activated carboxymethyl derivative in alkali, whereby O-carboxymethyl groups are introduced along the dextran chain.

Application

FITC-CM-dextran is used to study drug intake and delivery mechanisms in HeLa cell lines. FITC-CM-Dextran was chosen due to its high water solubility and negative charge.[1]

It is also a suitable molecule to be used in encapsulation studies for polymersomal drug delivery systems or Ps DDS[2] . FITC-CM-Dextran is a biocompatible molecule used as a starting material in several pharmaceutical and diagnostic applications.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
680595347153379
biological source

synthetic

biological source

synthetic

biological source

-

biological source

synthetic

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

form

powder or crystals

form

powder or crystals

form

powder or crystals

form

powder or crystals

composition

carboxymethyl content, 3-7%

composition

carboxymethyl content, 3-7%

composition

carboxymethyl content, 3-7%

composition

carboxymethyl content, 3-7%

fluorescence

λex 493 nm; λem 517 nm±5 nm in 0.1 M Tris pH 8.0

fluorescence

λex 493 nm; λem 517 nm±5 nm in 0.1 M Tris pH 8.0

fluorescence

λex 493 nm; λem 517 nm±5 nm in 0.1 M Tris pH 8.0

fluorescence

λex 493 nm; λem 517 nm±5 nm in 0.1 M Tris pH 8.0

mol wt

average mol wt 150,000

mol wt

average mol wt 4,000

mol wt

average mol wt 70,000

mol wt

average mol wt 40,000


Still not finding the right product?

Explore all of our products under FITC-CM-Dextran


Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen


Artikel

Explore FITC-labelled polysaccharides and their properties, including impact of molecular weight on molecule dimensions.


Marco Romano et al.
Oncoimmunology, 6(10), e1345402-e1345402 (2017-11-11)
Myelofibrosis (MF) is a clonal neoplasia associated with chronic inflammation due to aberrant cytokine production. Mutations in Janus Kinase-2 (JAK2), calreticulin (CALR) and myeloproliferative leukemia protein (MPL) genes have been recently associated to MF and they all activate the JAK/STAT
Chloe Martin et al.
International journal of pharmaceutics, 511(1), 570-578 (2016-07-28)
The need to develop a greater understanding of drug delivery systems has arisen through the development of alternative biological based therapeutics. Drug delivery systems need to adapt and respond to this increasing demand for cellular transportation of highly charged species.
Chloe Martin et al.
International journal of pharmaceutics, 481(1-2), 1-8 (2015-01-17)
The field of therapeutics is evolving to include a greater proportion of higher molecular weight, hydrophilic biological compounds. To cater for this new era in healthcare the concomitant development of appropriate drug delivery systems is essential to aid cellular permeation.



Global Trade Item Number

SKUGTIN
74817-1G04061823356183

Questions

Reviews

No rating value

Active Filters